BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays
News Apr 11, 2011
BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac’s FLEXYTE™ fluorescence lifetime (FLT) assays. FLT as a reading modality offers a robust, antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.
BioFocus has launched an FLT screening and profiling service utilizing the FLEXYTE™ assay platform and now offer campaigns against targets including proteases, phosphatases and kinases. The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes. Several approaches can be taken using the FLEXYTE™ platform including fragment based screens and kinetic profiling.
‘Being able to incorporate FLT in our service offering enables BioFocus to provide clients an approach to screening and profiling that will unlock significant potential within their drug discovery efforts’ commented Dr Kate Hilyard, VP Biological Sciences, BioFocus.
‘We are delighted that BioFocus has chosen to add our FLEXYTE™ platform to their service offering. We feel that this will allow a broad range of drug discovery groups access to the power of FLT’ said Dr Stephen Barr, President and Managing Director of Almac Sciences.
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018